First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7119-7125

  Dudek, Arkadiusz Z ^a   Yunis, Carla ^b   Harrison, Lester I ^b   Kumar, Sandeep ^b   Hawkinson, Ronald ^b   Cooley, Sarah ^a   Vasilakos, John P ^b   Gorski, Kevin S ^b   Miller, Jeffrey S ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b 3M COMPANY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

852 A; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CPG 2059; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMIQUIMOD; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P40; MITOMYCIN C; N [4 (4 AMINO 2 ETHYL 1H IMIDAZO[4,5 C]QUINOLIN 1 YL)BUTYL]METHANESULFONAMIDE; NITROSOUREA; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFUSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DEHYDRATION; DENDRITIC CELL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EMBRYO; ERYTHROCYTE COUNT; FATIGUE; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INNATE IMMUNITY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NATURAL KILLER CELL; NAUSEA; NEUTROPHIL COUNT; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PERONEUS NERVE PARALYSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE; COHORT STUDIES; CYTOKINES; DENDRITIC CELLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNITY, NATURAL; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; QUINOLINES; SENSITIVITY AND SPECIFICITY; SULFONAMIDES; TOLL-LIKE RECEPTOR 7;

EID: 37249041922     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1443     Document Type: Article

References (30)

1. Medzhitov R, Janeway C, Jr. The Toll receptor family and microbial recognition. Trends Microbiol 2000;8:452-6.
2. Evinger M, Maeda S, Pestka S. Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity. J Biol Chem 1981;256:2113-4.
3. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-70.
4. Haranaka K, Satomi N. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn J Exp Med 1981;51:191-4.
5. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99:23-33.
6. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147:2461-6.
7. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50:722-33.
8. Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006;54:1025-32.
9. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003;139:273-6.
10. Hengge UR, Roth S, Tannapfel A. Topical imiquimod to treat recurrent breast cancer. Breast Cancer Res Treat 2005;94:93-4.
11. Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk Lymphoma 2005;46:935-9.
12. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
13. Halls S. The Mosteller formula for calculating body surface area [online converter]. Vol. 2005, November 10, 2003.
14. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (excerpted), version 3.0, March 31, 2003. Bethesda: National Cancer Institute; 2003.
15. Harrison L, Astry C, Kumar S, et al. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 2007;47:962-9.
16. Chen W, Chan AS, Dawson AJ, Liang X, Blazar BR, Miller JS. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. Biol Blood Marrow Transplant 2005;11:23-34.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005;174:1259-68.
19. Gorski KS, Waller EL, Bjornton-Severson J, et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 2006;18:1115-26.
20. Gunzer M, Riemann H, Basoglu Y, et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 2005;106:2424-32.
21. Blackwell SE, Krieg AM. CpG-A-induced monocyte IFN-γ-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-α. J Immunol 2003;170:4061-8.
22. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002;218:74-86.
23. Ito T, Amakawa R, Kaisho T, et al. Interferon-α and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002;195:1507-12.
24. Coccia EM, Severa M, Giacomini E, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004;34:796-805.
25. Yano H, Yanai Y, Momosaki S, et al. Growth inhibitory effects of interferon-α subtypes vary according to human liver cancer cell lines. J Gastroenterol Hepatol 2006;21:1720-5.
26. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005;174:727-34.
27. Soria I, Myhre P, Horton V, et al. Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int J Clin Pharmacol Ther 2000;38:476-81.
28. Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004;296:6-11.
29. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
30. Torres A, Storey L, Anders M, et al. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med 2007;5:7.